105 related articles for article (PubMed ID: 15094747)
21. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
22. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547
[TBL] [Abstract][Full Text] [Related]
24. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
Hahn T; Benekli M; Wong C; Moysich KB; Hyland A; Michalek AM; Alam A; Baer MR; Bambach B; Czuczman MS; Wetzler M; Becker JL; McCarthy PL
Bone Marrow Transplant; 2005 Mar; 35(6):557-66. PubMed ID: 15665852
[TBL] [Abstract][Full Text] [Related]
25. Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.
Sperotto A; Damiani D; Zaja F; Patriarca F; Geromin A; Cerno M; Stocchi R; Tiribelli M; Skert C; Rinaldi C; Fanin R
Adv Clin Path; 2002 Apr; 6(2):77-85. PubMed ID: 19753729
[TBL] [Abstract][Full Text] [Related]
26. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
27. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
28. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
29. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
30. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
[TBL] [Abstract][Full Text] [Related]
31. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
Ardeshna KM; Kakouros N; Qian W; Powell MG; Saini N; D'Sa S; Mackinnon S; Hoskin PJ; Goldstone AH; Linch DC
Br J Haematol; 2005 Aug; 130(3):363-72. PubMed ID: 16042685
[TBL] [Abstract][Full Text] [Related]
32. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
33. Role of chemoresistance prior to autologous bone marrow transplantation for Hodgkin's disease.
Voillat L; Deconinck E; Flesch M; Brion A; Rozenbaum A; Vuillier J; Pavy JJ; Angonin R; Carbillet JP; Hervé P
Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):423-30. PubMed ID: 7753613
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
[TBL] [Abstract][Full Text] [Related]
35. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases.
Kim HJ; Bang SM; Lee J; Kwon HC; Suh C; Kim HJ; Lee JH; Ryoo BY; Park YH; Kwon JM; Oh SY; Lee HR; Kim K; Jung CW; Park K; Kim WS
Bone Marrow Transplant; 2006 May; 37(9):819-24. PubMed ID: 16547486
[TBL] [Abstract][Full Text] [Related]
36. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
[TBL] [Abstract][Full Text] [Related]
37. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease.
Wendland MM; Asch JD; Pulsipher MA; Thomson JW; Shrieve DC; Gaffney DK
Am J Clin Oncol; 2006 Apr; 29(2):189-95. PubMed ID: 16601441
[TBL] [Abstract][Full Text] [Related]
38. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
Schellong G; Dörffel W; Claviez A; Körholz D; Mann G; Scheel-Walter HG; Bökkerink JP; Riepenhausen M; Lüders H; Pötter R; Rühl U;
J Clin Oncol; 2005 Sep; 23(25):6181-9. PubMed ID: 16135485
[TBL] [Abstract][Full Text] [Related]
39. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
40. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
Glossmann JP; Staak JO; Nogova L; Diehl V; Scheid C; Kisro J; Reis HE; Peter N; Engert A; Josting A
Ann Hematol; 2005 Aug; 84(8):517-25. PubMed ID: 15759115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]